Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
incredibly rich, Dude!
Everybody already read this encouraging one?
investopedia 2015-03-06
'Keep in mind that Exelixis is by no means out of the woods just yet, ... However, ...
similar characters form similar physiognomies
Shorts - endangered species -
Let me shoot them with the bop gun - lol
if overall volume increase goes on like this shorts will get the status 'endangered species' lol
Disadvantage shorts!
short interest increase is half the truth as a single figure - since end of January we've been watching overall volume increase and for the shorts the days to cover fell from ten days to five and a half. short interest ratio = short interest : average daily trading volume
Short interest should always be looked at in comparison to the average daily volume, which went up - so we had less shorting here in Feb.
GLTA
Nasdaq-page - short interest
While Novo Nordisk (NYSE:NVO) has not made an official announcement with regard to its already approved anti-obesity drug Saxenda, there seems to be anecdotal evidence that we are about to get some information regarding the launch. Up until now, the company has only stated that the launch will happen in the first half of 2015, and that about 500 sales reps would be assigned Saxenda duties.
SeekingAlpha 2015-03-10
come on tell us more!
'That's why ARIA saw an Increase..'
Hey Guys, consider civic's thoughts on how the BR buy has to be gaged.
post on SI
I think we are at a point where the perception of Ariad in the eyes of the investment community may change. HB consciously may wants to get rid of those kind of investors looking for the quick money, to bring in more steadiness and less uncertainty and volatility. Old skool East Coast style, isn't it, but maybe he or the Ariad decision team is right to do so. The equity's burdon of a must to rebound still hangs in the air for more than one year now. Let's have a look whether this played politics will bring us success. Ariad's financial problems is of course another thing to discuss...
"Based on this plan, we expect to achieve sustained profitability based on more than $400 million in anticipated product revenue in 2018."
...and iga is "intergranular attack"
br thanks for pointing out that. Should be discussed here that on the horizon new basic approaches in fighting cancer in a more efficient way, while less saddled with AEs, appear, no, are already in work.
You don't have to be a pessimist to answer the question how Ariad might bring science results up to date as they massively reduced R&D? They won't keep pace with the development to more revolutionary drugs than the TKIs once have been.
Seems that the existence of Ariad ends in smoke when HB is going to retire some years from now. All they intend to do yet is making some money selling their two, maybe three molecules that are the results of 24 years of scientific research. Rida was a pop and no kick, AP1903 was sold, Iclusig is 3L/4L. Revenues are low but 21 cigars smoking every day for shareholder value, not!
If _113 and New_M are not the trump cards that are needed for a turn-around, future doesn't look that bright as some here make readers of this board think.
As everybody here knows there are several competitive anti-obesity drugs either to be marketed soon or awaiting approval by the FDA sooner or later.
On December 23rd Novo Nordisk's Saxenda was was approved by the FDA.
This might get approval very soon:
VBLOC device called Maestro by Enteromedics
Maestro
chances
Zafgen phase 2 and 3
Beloranib
Janssen
Canagliflozin
seeking alpha 2014-11-17
Rhythm 2x phase 2
Relamorelin
If obesity market continues to develop, in spite of an increasing number of drugs Orexigen has great potential to become a big player in that market. Analysts estimate the obesity market to sixfold till 2020!
And don't forget the potential Orexigen has in the EU as there it is almost the only company with an approved anti-obesity drug.
Hopefully the Q4/14 figures are positive and pps rises...
GLTA
TwoPack
nice EXEL outlook posted by rchites on yahoo board
Happy New Year to everybody here - the magnificent seven(ty) is coming some day
Sales in asian countries outside Japan will be disappointing for years compared to population figures.
longx thanks for your appraisal. If pona could get marketed in asian countries as Vietnam without preceding approval, fine for everyone. One question. I ask myself how can average cancer sick people over there afford the huge costs for pona? Isn't that a crux of the matter? Or does Ariad give a discount for asian countries outside Japan? You have any idea about how price politics could look like?
In Munich people don't drink bitburger at all, they prefer Augustiner lol
Should go up now again $$$$
Thanks MIT! You're right not to play the 50/50 game. Stay here till Wednesday or Thursday before following you outta here. Go in again after a positive decision.
Though I am a long here in Aria I appreciate Bio Researcher's postings as they often give us points of view from Ariad in BP system of coordinates many here are too euphoric, not to say disconnected from reality to see.
Hope must not rule out all sense of critical analysis - The World as Will and Representation if you know what I mean.
Not to be able to read BR's postings seems to be just big shakiness.
And here is my reply to your reply on jaybe's reply on my post lol:
"right. I know. That's why I changed the word 'competitor' to Amgen, because that could be misunderstood. You beat for it with your response ;)
Maybe Blincyto and its approval is interesting anyway, also in respect of ariad and the accelerated approval of...113."
link
thinkin' outside the box is a must here in BP.
Amgen gets immunotherapy drug against ALL-neg approved:
"The U.S. Food and Drug Administration today approved [Amgen's] Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL."
"Blincyto is the first approved drug that engages the body’s T-cells, a type of white blood cell or lymphocyte, to destroy leukemia cells."
"Blincyto is being approved under the FDA’s accelerated approval program... more than five months ahead of the prescription drug user fee goal date of May 19, 2015, the date the agency was scheduled to complete review of the application."
"Blincyto carries a boxed warning..."
FDA approves Blincyto
Can't blame her, she probably needs money. Proposed to build a house? It's certainly not because of sps development IMO:
Heather D. Turner, Senior Vice President, General Counsel & Secretary has been selling more or less amounts of shares for the third time since September:
SEC Filing No4 2014-12-04 Heather Turner
Agree with you MIT
The triangle has become a little wider IMO but still goes nicely with a possible breakout around Dec 19th ;) so course may drift on sideways now as you say.
At least we roughly hit the 5.90 by the end of this day closing at 5.83 :)
Good luck to you
@abbey
@zuize
Remember? In march JAZZ was dealt to be the Ariad purchaser? And sp even dropped as I remember.
DM - 2014-03-28
Excuse me Sir, Russia is no socialist country anymore - since 1992.
"The beginning of wisdom is to call things by their right names" chinese proverb
Sorry to say that you linked to a Wells Fargo rating dated sept 11
Here is the latest rating which is $ 9.50 - $ 10.50 ;)
StreetInsider.com
"Thankfully, I sold my position around $6 for a small gain"
You did the exact opposite of what you made everybody think in this board, selling instead of holding?
Should double from here
and
load the boat - Exactly
What about your tremendous losses since 9-11
No word about that!
I guess you're a shortie for sure
rufus
thanks for your elaboration on why contrave is more likely to succeed in getting approval in the EU than not. Like your style providing profound arguments. Can easily agree with these. Great post.
for me thats no bad mouthing but considering the facts
masha, rufus, conix thanks for posting your finds here!
always thought it would take 180 days, end of Jan 15, till EMA talks to us, so lets all hope for friday that this down beaten equity will be pushed up in direction where we startet from.
wouldn't mind if he goes to BK soon